CHMP adoptes positive opinion, for Tepezza (teprotumumab) for treatment of adults with moderate to severe thyroid eye disease – Amgen
The EMA has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe thyroid eye disease…. read more.